Table1 Echocardiography results for each group

From: Interferon-γ mediates the protective effects of soluble receptor for advanced glycation end-product in myocardial ischemia/reperfusion

 

sham

sRAGE

MI/R

MI/R + sRAGE

MI/R + sRAGE + anti-IFN-γ

HR

541.1 ± 65.93

527.8 ± 17.05

558.6 ± 28.24

571.0 ± 12.73

551.0 ± 34.78

LVEF (%)

65.5 ± 4.63

65.2 ± 3.95

23.3 ± 4.41**

46.9 ± 8.50#

30.1 ± 4.80&

FS (%)

35.6 ± 3.52

35.0 ± 2.94

12.0 ± 2.00***

30.6 ± 5.71###

12.2 ± 1.61&&

CO (mL/min)

20.0 ± 2.43

18.7 ± 1.03

13.6 ± 1.39*

17.0 ± 2.40

13.9 ± 2.10

SV (μL)

36.9 ± 1.43

35.6 ± 3.10

24.4 ± 2.53*

30.2 ± 4.81

22.7 ± 2.27

LVM (mg)

63.3 ± 3.86

66.9 ± 1.09

68.0 ± 2.15

72.1 ± 4.07

67.4 ± 5.86&

LVEDV (μL)

63.2 ± 3.01

56.8 ± 1.46

88.6 ± 4.76*

60.8 ± 9.52#

105.8 ± 9.71&&&

LVESV (μL)

23.8 ± 2.04

20.0 ± 0.01

65.6 ± 7.16**

28.4 ± 9.13##

95.8 ± 11.1&&&

LVEDD (mm)

4.0 ± 0.24

3.6 ± 0.04

4.2 ± 0.29

3.8 ± 0.27

4.3 ± 0.29

LVESD (mm)

2.9 ± 0.33

2.3 ± 0.08

3.9 ± 0.20

2.9 ± 0.36

3.8 ± 0.34

  1. All the values were expressed as mean ± SEM and calculated from at least five mice in each group
  2. MI/R myocardial ischemia/reperfusion, HR heart rate, LVEF left ventricular ejection fraction, FS fractional shortening, CO cardiac output, SV stroke volume, LVM left ventricular mass, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter
  3. *p   < 0.05 vs sham; **p   < 0.01 vs sham; ***p   < 0.001 vs sham; #p  <  0.05 vs MI/R; ##p   < 0.01 vs MI/R; ###p   < 0.001 vs MI/R; &p  < 0.05 vs MI/R + sRAGE; &&p   < 0.01 vs MI/R + sRAGE; &&&p <  0.001 vs MI/R + sRAGE
Back to article page